Superworth

Corcept Therapeutics profit margin CORT

Gross, operating and net profit as a share of revenue over the last twelve months, from 2015.

Net margin, 12 months
6.6%
Operating margin, 12 months
0.8%
Net margin on a year earlier
−12.0 pts
Peer median
15.0%

Over the twelve months to Jun 30, 2026, Corcept Therapeutics kept 6.6% of its revenue as net profit, with an operating margin of 0.8% and a gross margin of 98.3%.

Five years earlier its net margin was 28.4%.

The median for 10 large drugmakers of a similar size is 15.0%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202513.1%5.9%98.3%
FY202420.9%20.3%98.4%
FY202322.0%22.2%98.7%
FY202225.2%28.0%98.7%
FY202130.7%34.0%98.6%
FY202030.0%36.2%98.4%
FY201930.7%36.4%98.2%
FY201830.0%35.6%97.9%
FY201781.1%33.2%97.8%
FY201610.0%12.5%97.5%
FY2015−12.7%−6.8%97.3%
FY2014n/an/a96.7%
FY2013n/an/a98.6%
FY2012n/an/an/a
FY2011n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY266.6%−12.0 pts0.8%
Q1 FY266.2%−13.4 pts−1.1%
Q4 FY2513.1%−7.8 pts5.9%
Q3 FY2514.3%−8.2 pts8.8%
Q2 FY2518.7%−3.5 pts14.2%
Q1 FY2519.5%−3.0 pts16.2%
Q4 FY2420.9%−1.1 pts20.3%
Q3 FY2422.6%+2.3 pts22.8%
Q2 FY2422.1%+0.0 pts22.5%
Q1 FY2422.5%−0.3 pts23.3%
Q4 FY2322.0%−3.2 pts22.2%
Q3 FY2320.3%−9.1 pts21.8%

Against its peers

Companies in Drug Manufacturers - General nearest Corcept Therapeutics' size, closest first, today.

CompanyProfit margin
CORTCorcept Therapeutics6.6%
PTGXProtagonist Therapeutics29.4%
TGTXTG Therapeutics55.2%
BMRNBiomarin Pharmaceutical2.1%
ALKSAlkermes plc.4.0%
AMRXAmneal Pharmaceuticals5.0%
JAZZJazz Pharmaceuticals20.4%
LGNDLigand Pharmaceuticals67.9%
KNSAKiniksa Pharmaceuticals International9.6%
INDVIndivior Pharmaceuticals26.7%
ARQTArcutis Biotherapeutics6.1%
Peer median15.0%

Where Corcept Therapeutics ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Corcept Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.